AptarGroup buys up Nanopharm, Gateway Analytical as it looks to broaden reach

BD exiting sterile injectables biz, selling plant and portfolio to Fresenius Kabi
Nanopharm designs and develops oral and nasal pharma products, while Gateway focuses on companies working on injectables. (Getty Images)

Illinois-based AptarGroup is looking to reach out further into biopharma servicing with the acquisitions of Nanopharm and Gateway Analytical.

This will be a change-up for AptarGroup, which currently supplies dispensing, sealing and active packaging for a range of industries including beauty, personal care and home care as well as prescription drugs and injectables.

With the new purchases, which it says are “for a combined enterprise value of approximately $50 million,” it will boost its Aptar Pharma unit’s offerings.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Nanopharm, which is based in the U.K., works on orally inhaled and nasal drug product design and development services. Gateway Analytical, located in Gibsonia, Pennsylvania, offers detection and predictive analytical services to customers working on injectables.

“The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments,” the company said in a statement.

“We are delighted to welcome the talented teams of Nanopharm and Gateway and their customers to Aptar Pharma,” said Gael Touya, president of Aptar Pharma. “Their expertise and capabilities will deepen our current range of services offered to customers who are developing and testing inhaled and injected medicines. This enables us to participate in a broader spectrum of the pre-clinical, clinical trial and market launch phases of drug development.”

Stephan Tanda, president and CEO of AptarGroup, added: “These strategic investments further strengthen our best in class Pharma business and increase our ability to add to our long-term growth pipeline by adding depth to our service offerings.

“The expertise of two established leaders, Nanopharm, a leader in inhalation and nasal drug development services, and Gateway, a leader in particulate detection and analysis for the injectables market, are complementary to our existing laboratory and analytical services and will bring additional value to our customers as they navigate the challenging regulatory landscape and seek to bring their products to market faster.”

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.